Human Vaccine Market in China 2018 Forecasts (Hib, Human Rabies, Varicella, Influenza) Research Reports


DALLAS, March 27, 2015 /PRNewswire/ --

This research says Being bullish about China's demand for human vaccines and exports, many vaccine producers scale up efforts in vaccine R&D or expand capacity, such as Walvax Biotechnology.

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies' (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China's human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

Major Chinese Vaccine Producers
China National Biotec Group Co., Ltd., Hualan Biological Engineering Inc., Chongqing Zhifei Biological Products Co., Ltd., Walvax Biotechnology Co., Ltd., Sinovac Biotech Ltd., Liaoning Chengda Co., Ltd., Changchun BCHT Biotechnology Co. Ltd., Changchun Changsheng Life Sciences Limited, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Dalian Hissen Bio-pharm Co., Ltd., NCPC GeneTech Biotechnology Development Co., Ltd., Dalian Aleph Biomedical Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd., Shenzhen Sanofi Pasteur Biological Products Co., Ltd., Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.

Human Vaccine Market Segments in China
Hepatitis B Vaccine, Meningococcal Vaccine, Hepatitis A Vaccine, Influenza Vaccine, Hib Vaccine, Human Rabies Vaccine, Varicella Vaccine, Pneumococca Vaccine, DTP Vaccine, Poliomyelitis Vaccine

Order a copy of this report (China Human Vaccine Industry Report, 2015-2018) athttp://www.rnrmarketresearch.com/contacts/purchase?rname=329371  .

Affected by China's less-developed economy, existing national vaccine prevention policies and people's awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.

However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume. Moreover, private and foreign brands hold a dominant position in the markets of Haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, and influenza vaccine, together making up 91.9%, 83.6%, 86.5%, and 69.5% in terms of lot release volume in 2014.

By early 2015, GMP on-site certification had been carried out for the company's Diphtheria-tetanus-acellular pertussis combined vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and DTaP/Hib had made their way into clinical trials; the company is applying registration for meningococcal polysaccharide vaccine (Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru, Thailand, and India.

China Human Vaccine Industry Report, 2015-2018  highlights the following:

Operating environment, overall situation, sales channel, etc. of China human vaccine industry;
Supply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
Supply & demand, competitive landscape, and market prices of 10 product segments (including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine) in China;
Operation, vaccine business, and development prospects of 16 Chinese human vaccine companies.
Related Report

Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively.

The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year.

As China's vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015.

Browse more reports on "Diseases & treatment" at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
[email protected]
Connect with Us:

G+ / Google Plus:https://plus.google.com/u/0/104156468549256253075/

Twitter:https://twitter.com/RnRMR

Facebook:https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds:http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.